ProQR (PRQR)
NASDAQ:PRQR
Want to see PRQR full AI Analyst Report?
PRQR Stock Chart & Stats
$1.99
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.99
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.31 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$193.86M
Enterprise Value$77.47M
Total Cash (Recent Filing)$92.37M
Total Debt (Recent Filing)$13.99M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Apr 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue4.87
Enterprise Value/Gross Profit5.09
Enterprise Value/Ebitda-1.92
Forecast
1Y Price Target
$8.20Price Target Upside312.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$23.20M
Bulls Say, Bears Say
Bulls Say
Clinical Proof Of ConceptEarly AX-0810 dosing showed a clean safety profile with liver exposure consistent with expectations, supporting initial proof of concept for the RNA editing platform.
Pipeline Expansion And Discovery AccelerationIntroduction of next-generation candidates and an AI-enabled discovery engine expands the pipeline and could accelerate design and progression of editing oligonucleotides, improving future program productivity.
Target Engagement BiomarkerAnticipated biomarker changes, including sustained serum bile acid elevation, would demonstrate persistent target engagement and could differentiate the RNA editing approach from peptide inhibitors or daily oral therapies.
Bears Say
Platform Concentration RiskHeavy reliance on a single RNA editing platform means setbacks in demonstrating human editing could disproportionately affect company valuation and investor confidence.
Regulatory And Clinical Interpretability RiskDifficulty in producing clinically interpretable editing signals could complicate establishment of regulatory endpoints and delay demonstration of therapeutic benefit.
Translational RiskThe investment thesis depends on the RNA editing platform delivering clear, clinically interpretable editing in humans, a capability that remains unproven and poses execution risk.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.31 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $193.86M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Apr 30, 2026 which is in 8 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Mar 12, 2026. The company reported -$0.094 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.011.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.14.
How many shares outstanding does ProQR have?
ProQR has 105,361,060 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.094 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went down -4.972%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.20 (312.06% Upside)
$8.20 (312.06% Upside)
Hedge Fund Trend
Decreased
By 92.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 97.7%
Last 30 Days ▲ 97.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-65.10%
Trailing 12-Months
Asset Growth
-23.86%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.20
▲(312.06% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.35% Mutual Funds
0.17% Other Institutional Investors
97.07% Public Companies and
Individual Investors